Injection better at HIV protection than daily pills: U.S. researchers  Japan TodayView Full coverage on Google News
Injecting people with a new, experimental drug every eight weeks provides better protection against HIV than daily pills that have revolutionized the fight against AIDS, U.S. government researchers report. The National Institutes of Health released the preliminary results of a major clinical trial involving a drug called cabotegravir. The testing…

Injection better at HIV protection than daily pills: U.S. researchers - Japan Today

GlobalData believes that the results of this study did not show cabotegravir to be statistically superior to Truvada to prevent HIV.GlobalData believes that the results of this study did not show cabotegravir to be statistically superior to Truvada to prevent HIV.

Cabotegravir more effective than Truvada for prevention of HIV

Dr. John Carlo Trials of Cabotegravir so successful, GSK ends trials early Tammye Nash | Managing Editor nash@dallasvoice.com HIV Advocates this week applauded news of a new drug for use in pre-exposure prophylaxis regimens that has proven so successful in trials that the trials were ended early. ViiV Healthcare — majority owned by GlaxoSmithKline with […]

HIV advocates hail new long-lasting PrEP option - Dallas Voice

The long-acting antiretroviral drug is administered every two months.The long-acting antiretroviral drug is administered every two months.

New injectable drug prevents HIV infections, study reveals - Daily Nation

“For years, pre-exposure prophylaxis (PrEP) has been the standard of care for preventing new HIV infections. However, a study released this morning has shown that an antiretroviral drug called cabotegravir had a 69% decline in new infection rates compared to PrEP.”

Liz Szabo on Twitter: "For years, pre-exposure prophylaxis (PrEP) has been the standard of care for preventing new HIV infections. However, a study released this morning has shown that an antiretroviral drug called cabotegravir had a 69% decline in new infection rates compared to PrEP."

The study was stopped early after the trial achieved the primary end point of noninferiority with the difference approaching superiority for cabotegravir.The study was stopped early after the trial achieved the primary end point of noninferiority with the difference approaching superiority for cabotegravir.

Long-Acting Injectable Cabotegravir Noninferior to Oral PrEP in HIV Prevention Study - MPR